Lactobacillus Rhamnosus GG Alleviates Oral Mucositis in Patients Undergoing Radiotherapy

Launched by WEST CHINA HOSPITAL · Apr 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether a probiotic called Lactobacillus rhamnosus GG (LGG) can help reduce a painful condition called oral mucositis in patients undergoing radiation therapy for head and neck cancers. Oral mucositis is a common side effect of radiation that affects the mouth and throat, making it hard to eat and drink. The trial is open to adults aged 18 to 80 who have been diagnosed with certain types of head and neck tumors and are planning to receive radiation treatment.

If you or a loved one qualify for this trial, you can expect to take LGG daily during the radiation therapy. The researchers hope to see if this probiotic can make the treatment easier by reducing the severity of oral mucositis, ultimately improving the quality of life for patients. It's important to note that those with certain allergies, previous radiation therapy, or serious medical conditions may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients pathologically diagnosed with non-metastatic head and neck malignant tumors;
• • 2. Aged 18-80 years;
• • 3. Eastern Cooperative Oncology Group performance status of ≤2;
• • 4. Planning to receive definitive RT or postoperative adjuvant RT;
• • 5. Normal liver, kidney and bone marrow function;
• • 6. Sign informed consent.
• Exclusion Criteria:
• • 1. Known hypersensitivity or more severe allergies to Lactobacillus Reuteri components;
• • 2. Those with poor compliance;
• • 3. Pregnancy or breastfeeding;
• • 4. History of head and neck radiotherapy;
• • 5. Taking antifungal or viral medications one week prior to the start of radiation therapy.
• • 6. Other patients (with any other serious other medical condition) who, in the opinion of the investigator, are not suitable for participation in this study.